11:12:10 Europe / Stockholm
Svenska | English

Gubra

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-08-23 Kvartalsrapport 2024-Q2
2024-04-04 Ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-01 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
Invitation to the presentation of Gubra’s Q1-2023 results
2023-05-09 13:41:00

Gubra will host a conference call for investors, analysts and media on Thursday, May 11, 2023, at 10:00am CET. The company's Q1-2023 Trading Statement will be published on the same day at 7:30am CET.

The conference call will be hosted by the company’s CEO Henrik Blou, CSO Niels Vrang and CFO Kristian Borbos. The presentation will be held in English. To participate in the conference call, please use the following dial-ins:
DK: +45 3274 0710
UK: +44 20 3481 4247

When dialling-in, please state the name of the call “Gubra Q1-2023 earnings release” or the conference ID: 3734401

The presentation can also be followed live via the link: https://events.q4inc.com/attendee/322801355/guest

It will be possible to listen to the presentation afterwards at the abovementioned link.

Presentation material for the conference call will be uploaded on Gubra - Investor Relations before the call.

Contacts
Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Us
Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments
Invitation to the presentation of Gubra’s Q1-2023 results

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden